Physiomics plc announced that it has been awarded a substantial new contract by an existing large pharma client. The project involves Pharmacokinetic-Pharmacodynamic (PKPD) modelling in the field of DNA damage/repair field and will help inform clinical dose and scheduling decisions. The value of the project is £178,000 and it is anticipated that it will be completed over the course of the next six months.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.25 GBX | 0.00% | 0.00% | -21.88% |
05-03 | Physiomics warns large contracts taken longer than expected | AN |
05-03 | AIM WINNERS & LOSERS: Fletcher King optimistic; Angle in Astra deal | AN |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-21.88% | 2.15M | |
-0.63% | 137B | |
+20.13% | 77.04B | |
-9.44% | 40.58B | |
+1.78% | 31.11B | |
-5.15% | 17.25B | |
+14.77% | 15.32B | |
+9.68% | 10.44B | |
-9.06% | 4.71B | |
-35.96% | 3.96B |
- Stock Market
- Equities
- PYC Stock
- News Physiomics Plc
- Physiomics plc Wins Contract by an Existing Pharma Client